Advancing the Cardiovascular Care of the Oncology Patient
COURSE OVERVIEW/STATEMENT OF NEED
Cardiovascular disease is the second leading cause of morbidity and mortality in cancer survivors. Since an estimated 14.5 million cancer patients and survivors have significant cardiovascular risk factors, it is critical for cardiologists, oncologists, and the entire multi-professional care team to stay on the leading edge of this rapidly evolving field. Advancing the Cardiovascular Care of the Oncology Patient provides clinicians and researchers with the tools needed to improve patient care in your everyday practice.
Over the past 4 years, the American College of Cardiology has joined forces with respected experts in the field of Cardio-oncology to develop a program covering the most relevant and required content for both the novice and advancing practitioner. Join us at Advancing the Cardiovascular Care of the Oncology Patient and engage with our growing community. Participate through interactive case discussions on evidence-based treatment strategies that address pre, intra and post-chemotherapy heart health. Throughout the course, you’ll have the unique opportunity to engage with expert faculty and a network of colleagues centered around ensuring your patients receive the most informed care possible.
Goal
The overall goal of this course is to provide clinically relevant, state-of-the-art, best practice strategies for the interprofessional team in the assessment, diagnosis and management of cardiovascular concerns for patients with cancer and/or those requiring survivorship care.
Learner Objectives
Coming Soon
Target Audience
The target audience is cardiovascular specialists, oncologists, internists, and all members of the multi-professional care team (including advanced practice providers, pharmacists, nurses) who are providing clinical care to the growing population of cancer patients and survivors with cardiovascular concerns.
2019 Pre-conference Educational Seminar: Pharmacologic Review of Cancer Therapy Essentials
We will kick off Friday evening with an optional, limited-seating pre-conference entitled Pharmacologic Review of Cancer Therapy Essentials: Anthracyclines, Her2+ Targeted Therapy, Immunotherapy, Tyrosine Kinase Inhibitors, Proteasome Inhibitors.
Friday, February 14, 2020
4:00 p.m. – 6:30 p.m. at Heart House
Pre-conference Registration Rate = $100
15% Discount to Pre-conference if included with course registration – ends October 24, 2019
Limited Seating 110 people – Register Early and SAVE